Journal article 467 views 69 downloads
Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
Fabrizio Schifano 
,
Stefania Bonaccorso,
Davide Arillotta ,
Amira Guirguis ,
John Martin Corkery ,
Giuseppe Floresta ,
Gabriele Duccio Papanti Pelletier,
Norbert Scherbaum ,
Nicolò Schifano
,
Stefania Bonaccorso,
Davide Arillotta ,
Amira Guirguis ,
John Martin Corkery ,
Giuseppe Floresta ,
Gabriele Duccio Papanti Pelletier,
Norbert Scherbaum ,
Nicolò Schifano
Brain Sciences, Volume: 15, Issue: 5, Start page: 424
Swansea University Author:
Amira Guirguis
-
PDF | Version of Record
© 2025 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Download (342.95KB)
DOI (Published version): 10.3390/brainsci15050424
Abstract
Background: “Chemsex” involves the intake of a range of drugs (e.g., synthetic cathinones, gamma-hydroxybutyric acid/gamma-butyrolactone (GHB/GBL), ketamine, methamphetamine, “poppers”, type V phosphodiesterase (PDE) inhibitors, MDMA/ecstasy, cocaine, cannabis, and occasionally a few other molecules...
| Published in: | Brain Sciences |
|---|---|
| ISSN: | 2076-3425 |
| Published: |
MDPI AG
2025
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa69313 |
| first_indexed |
2025-04-19T11:12:57Z |
|---|---|
| last_indexed |
2025-05-22T04:48:34Z |
| id |
cronfa69313 |
| recordtype |
SURis |
| fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2025-05-21T10:39:57.4830420</datestamp><bib-version>v2</bib-version><id>69313</id><entry>2025-04-19</entry><title>Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues</title><swanseaauthors><author><sid>b49270b9a0d580cf4f31f9a1b6c93f87</sid><ORCID>0000-0001-8255-0660</ORCID><firstname>Amira</firstname><surname>Guirguis</surname><name>Amira Guirguis</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2025-04-19</date><deptcode>MEDS</deptcode><abstract>Background: “Chemsex” involves the intake of a range of drugs (e.g., synthetic cathinones, gamma-hydroxybutyric acid/gamma-butyrolactone (GHB/GBL), ketamine, methamphetamine, “poppers”, type V phosphodiesterase (PDE) inhibitors, MDMA/ecstasy, cocaine, cannabis, and occasionally a few other molecules as well, to enhance and prolong sexual experiences. This paper aims to provide an overview of the clinical pharmacology of the vast range of drugs that are being used for chemsex with a focus on both the medical and psychopathological disturbances that they can produce. Methods: A narrative literature review was conducted using Pubmed, Scopus, and Web of Science databases. A total of 273 papers published up to January 2025 were screened; articles were selected based on relevance to chemsex/sexualized used behaviour and related substances. Both human and preclinical studies were considered. Results: The use of stimulants is likely related to the need to increase as much as possible both sexual arousal and performance but also to increase social interactions. Furthermore, the empathogenic/entactogenic activities of some MDMA-like “love drugs” facilitate the occurrence of “feeling closer/more intimate” emotional sensations, and GHB/GBL may provide the user with a subjective sensation of disinhibition, hence facilitating condomless meetings with a higher number of random partners. Conversely, ketamine may be used to both enjoy its psychotropic dissociative characteristics and facilitate the potentially painful receptive anal intercourse and/or fisting experiences. Most typically, these drugs are consumed in combination, with polydrug exposure possibly facilitating the occurrence of serotonergic syndrome, seizures, drug–drug pharmacokinetics’ interaction, and sympathomimetic overstimulation. Following these polydrug exposures, a range of psychopathological conditions have at times been reported. These issues may lead to misuse of opiates/opioids, gabapentinoids, and/or antipsychotics. Conclusions: Further actions should aim at reducing the stigma that prevents individuals from accessing necessary healthcare and support services. A multidisciplinary approach that combines medical, psychological, and social support remains key to managing the complex challenges posed by chemsex-related drug use.</abstract><type>Journal Article</type><journal>Brain Sciences</journal><volume>15</volume><journalNumber>5</journalNumber><paginationStart>424</paginationStart><paginationEnd/><publisher>MDPI AG</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2076-3425</issnElectronic><keywords>chemsex; sexualized drug behaviour; drug use; substance misuse; drug addiction</keywords><publishedDay>22</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2025</publishedYear><publishedDate>2025-04-22</publishedDate><doi>10.3390/brainsci15050424</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Other</apcterm><funders/><projectreference/><lastEdited>2025-05-21T10:39:57.4830420</lastEdited><Created>2025-04-19T12:03:17.8961375</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Pharmacy</level></path><authors><author><firstname>Fabrizio</firstname><surname>Schifano</surname><orcid>0000-0002-4178-5401</orcid><order>1</order></author><author><firstname>Stefania</firstname><surname>Bonaccorso</surname><order>2</order></author><author><firstname>Davide</firstname><surname>Arillotta</surname><orcid>0000-0002-8843-0595</orcid><order>3</order></author><author><firstname>Amira</firstname><surname>Guirguis</surname><orcid>0000-0001-8255-0660</orcid><order>4</order></author><author><firstname>John Martin</firstname><surname>Corkery</surname><orcid>0000-0002-3849-817x</orcid><order>5</order></author><author><firstname>Giuseppe</firstname><surname>Floresta</surname><orcid>0000-0002-0668-1260</orcid><order>6</order></author><author><firstname>Gabriele Duccio Papanti</firstname><surname>Pelletier</surname><order>7</order></author><author><firstname>Norbert</firstname><surname>Scherbaum</surname><orcid>0000-0003-1759-6990</orcid><order>8</order></author><author><firstname>Nicolò</firstname><surname>Schifano</surname><orcid>0000-0003-4828-4316</orcid><order>9</order></author></authors><documents><document><filename>69313__34169__97ea41807ae54a50812d53ac602456ab.pdf</filename><originalFilename>69313.VOR.pdf</originalFilename><uploaded>2025-05-02T13:33:05.8721465</uploaded><type>Output</type><contentLength>351178</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© 2025 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
| spelling |
2025-05-21T10:39:57.4830420 v2 69313 2025-04-19 Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues b49270b9a0d580cf4f31f9a1b6c93f87 0000-0001-8255-0660 Amira Guirguis Amira Guirguis true false 2025-04-19 MEDS Background: “Chemsex” involves the intake of a range of drugs (e.g., synthetic cathinones, gamma-hydroxybutyric acid/gamma-butyrolactone (GHB/GBL), ketamine, methamphetamine, “poppers”, type V phosphodiesterase (PDE) inhibitors, MDMA/ecstasy, cocaine, cannabis, and occasionally a few other molecules as well, to enhance and prolong sexual experiences. This paper aims to provide an overview of the clinical pharmacology of the vast range of drugs that are being used for chemsex with a focus on both the medical and psychopathological disturbances that they can produce. Methods: A narrative literature review was conducted using Pubmed, Scopus, and Web of Science databases. A total of 273 papers published up to January 2025 were screened; articles were selected based on relevance to chemsex/sexualized used behaviour and related substances. Both human and preclinical studies were considered. Results: The use of stimulants is likely related to the need to increase as much as possible both sexual arousal and performance but also to increase social interactions. Furthermore, the empathogenic/entactogenic activities of some MDMA-like “love drugs” facilitate the occurrence of “feeling closer/more intimate” emotional sensations, and GHB/GBL may provide the user with a subjective sensation of disinhibition, hence facilitating condomless meetings with a higher number of random partners. Conversely, ketamine may be used to both enjoy its psychotropic dissociative characteristics and facilitate the potentially painful receptive anal intercourse and/or fisting experiences. Most typically, these drugs are consumed in combination, with polydrug exposure possibly facilitating the occurrence of serotonergic syndrome, seizures, drug–drug pharmacokinetics’ interaction, and sympathomimetic overstimulation. Following these polydrug exposures, a range of psychopathological conditions have at times been reported. These issues may lead to misuse of opiates/opioids, gabapentinoids, and/or antipsychotics. Conclusions: Further actions should aim at reducing the stigma that prevents individuals from accessing necessary healthcare and support services. A multidisciplinary approach that combines medical, psychological, and social support remains key to managing the complex challenges posed by chemsex-related drug use. Journal Article Brain Sciences 15 5 424 MDPI AG 2076-3425 chemsex; sexualized drug behaviour; drug use; substance misuse; drug addiction 22 4 2025 2025-04-22 10.3390/brainsci15050424 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Other 2025-05-21T10:39:57.4830420 2025-04-19T12:03:17.8961375 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Pharmacy Fabrizio Schifano 0000-0002-4178-5401 1 Stefania Bonaccorso 2 Davide Arillotta 0000-0002-8843-0595 3 Amira Guirguis 0000-0001-8255-0660 4 John Martin Corkery 0000-0002-3849-817x 5 Giuseppe Floresta 0000-0002-0668-1260 6 Gabriele Duccio Papanti Pelletier 7 Norbert Scherbaum 0000-0003-1759-6990 8 Nicolò Schifano 0000-0003-4828-4316 9 69313__34169__97ea41807ae54a50812d53ac602456ab.pdf 69313.VOR.pdf 2025-05-02T13:33:05.8721465 Output 351178 application/pdf Version of Record true © 2025 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. true eng https://creativecommons.org/licenses/by/4.0/ |
| title |
Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues |
| spellingShingle |
Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues Amira Guirguis |
| title_short |
Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues |
| title_full |
Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues |
| title_fullStr |
Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues |
| title_full_unstemmed |
Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues |
| title_sort |
Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues |
| author_id_str_mv |
b49270b9a0d580cf4f31f9a1b6c93f87 |
| author_id_fullname_str_mv |
b49270b9a0d580cf4f31f9a1b6c93f87_***_Amira Guirguis |
| author |
Amira Guirguis |
| author2 |
Fabrizio Schifano Stefania Bonaccorso Davide Arillotta Amira Guirguis John Martin Corkery Giuseppe Floresta Gabriele Duccio Papanti Pelletier Norbert Scherbaum Nicolò Schifano |
| format |
Journal article |
| container_title |
Brain Sciences |
| container_volume |
15 |
| container_issue |
5 |
| container_start_page |
424 |
| publishDate |
2025 |
| institution |
Swansea University |
| issn |
2076-3425 |
| doi_str_mv |
10.3390/brainsci15050424 |
| publisher |
MDPI AG |
| college_str |
Faculty of Medicine, Health and Life Sciences |
| hierarchytype |
|
| hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
| hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
| department_str |
Swansea University Medical School - Pharmacy{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Pharmacy |
| document_store_str |
1 |
| active_str |
0 |
| description |
Background: “Chemsex” involves the intake of a range of drugs (e.g., synthetic cathinones, gamma-hydroxybutyric acid/gamma-butyrolactone (GHB/GBL), ketamine, methamphetamine, “poppers”, type V phosphodiesterase (PDE) inhibitors, MDMA/ecstasy, cocaine, cannabis, and occasionally a few other molecules as well, to enhance and prolong sexual experiences. This paper aims to provide an overview of the clinical pharmacology of the vast range of drugs that are being used for chemsex with a focus on both the medical and psychopathological disturbances that they can produce. Methods: A narrative literature review was conducted using Pubmed, Scopus, and Web of Science databases. A total of 273 papers published up to January 2025 were screened; articles were selected based on relevance to chemsex/sexualized used behaviour and related substances. Both human and preclinical studies were considered. Results: The use of stimulants is likely related to the need to increase as much as possible both sexual arousal and performance but also to increase social interactions. Furthermore, the empathogenic/entactogenic activities of some MDMA-like “love drugs” facilitate the occurrence of “feeling closer/more intimate” emotional sensations, and GHB/GBL may provide the user with a subjective sensation of disinhibition, hence facilitating condomless meetings with a higher number of random partners. Conversely, ketamine may be used to both enjoy its psychotropic dissociative characteristics and facilitate the potentially painful receptive anal intercourse and/or fisting experiences. Most typically, these drugs are consumed in combination, with polydrug exposure possibly facilitating the occurrence of serotonergic syndrome, seizures, drug–drug pharmacokinetics’ interaction, and sympathomimetic overstimulation. Following these polydrug exposures, a range of psychopathological conditions have at times been reported. These issues may lead to misuse of opiates/opioids, gabapentinoids, and/or antipsychotics. Conclusions: Further actions should aim at reducing the stigma that prevents individuals from accessing necessary healthcare and support services. A multidisciplinary approach that combines medical, psychological, and social support remains key to managing the complex challenges posed by chemsex-related drug use. |
| published_date |
2025-04-22T05:29:12Z |
| _version_ |
1856986732303482880 |
| score |
11.096068 |